Neovascular Age-related Macular DegenerationNCT04907409
Home OCT Fluid Visualization Agreement Study
An observational study of Neovascular Age-related Macular Degeneration, run by Notal Vision Inc. at 7 sites in United States.
Trial summary
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Neovascular Age-related Macular Degeneration
- How many people
- 120 participants
- Where
- 7 sitesUnited States
- Study dates
- 17 Jun 2021to 30 Aug 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult subjects diagnosed with neovascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment.
Who may be able to join
- Subjects must have the ability to speak, read and understand English.
- Ability to understand and agree to contents of informed consent either in writing or verbally.
- Age 55 or older at the Enrollment Visit.
- Adults diagnosed with NV-AMD in at least one eye based on the subject's medical record. Fellow eyes diagnosed with dry AMD may be included as secondary eyes to a primary eye diagnosed with NV-AMD.
- Note: eyes whit other pathologies including pseudocysts, outer retinal tabulations, pigments epithelial, detachments, hemorrhage, sub retinal hyper reflective material (SHRM), geographic atrophy and sub RPE, hypo reflective areas can be enrolled.
- Best corrected Visual Acuity of 20/320 or better in eyes that will perform self-imaging.
- Available and willing to set up a device and conduct self-imaging at their home.
Who cannot join
- Anti-VEGF treatment for NV-AMD in the study eye(s) at the screening visit.
- Any other retinal disease requiring steroidal or anti-VEGF injections.
- Prior experience with the NVHO device.
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
Ophthalmic Cons. of Boston
Boston, Massachusetts, 02114
Jamie Szczepanski, 617-314-2636, jszczepanski@eyeboston.com
Sandy Chong, 617-314-2627, schong@eyeboston.com
- Recruiting
Pepose Vision Institute/Midwest Vision Research Foundation
Chesterfield, Missouri, 63017
Roxanne Canter, 636-534-5126, rcanter@midwestvrf.org
Nancy Holekamp, MD
- Recruiting
Elman Retina Group, P.A.
Glen Burnie, Maryland, 21061
JoAnn Starr, 410-686-3000, Starr@elmanretina.com
Michael J. Elman, MD
- Recruiting
Retina Associates of Kentucky
Lexington, Kentucky, 40509
Diana Holcomb, 859-264-2905, dholcomb@retinaky.com
Sean Massey, 859-264-2905, smassey@retinaky.com
- Recruiting
Georgia Retina
Marietta, Georgia, 30060
Stephanie Hurst, scampbell@garetina.com
Leslie Marcus, 770-218-1888, lmarcus@garetina.com
- Recruiting
Wagner Macula & Retina Center
Norfolk, Virginia, 23502
Michael Boboc, mboboc@wagnerretina.com
Chris Riebling Riebling, 757-390-2433, criebling@wagnerretina.com
- Recruiting
Virginia Eye Institute
Richmond, Virginia, 23230
Lea Anderlini, 804-287-4250, anderlinil@vaeye.com
Byron S. Ladd, MD
About this study
Official title: Home OCT Fluid Visualization Agreement Study at Multiple Retinal Clinics With Placement of One Home OCT Device in the Home of Each NV-AMD Subject in the US for 5 Weeks
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.
Read the detailed description
The objectives of this study are to (1) evaluate the agreement, via positive percent agreement (PPA) and negative percent agreement (NPA), between OCT images captured by the NVHO and by the Zeiss Cirrus HD-OCT in the visualization of fluid as identified by a RC, in the central 10 degrees of the macula of NV-AMD patients, and (2) evaluate the ability of subjects diagnosed with NV-AMD to set up the device and self-image their eyes at home with the NVHO device (rate of successful imaging attempts).Description of Study Visits and Procedures:
Enrollment Visit:
At this visit, the exams will be conducted in the following order:
- Subject will be informed concerning the study and sign the Informed Consent Form (ICF) prior to the conduct of any study procedures.
- The following data will be collected for each study subject:
- Subject's date of birth (DOB) (if allowed) or age
- Gender
- Race
- Ethnicity
- Level of education
- Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma), will be performed on both eyes on the day of the visit.
- Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mm X 6mm, 512 X 128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
- One or both eye(s) of the subject that meets all screening criteria, including having a diagnosis of NV-AMD in at least one eye previously or at the enrolment visit, will be enrolled in the study.
- Subjects who do not meet all screening criteria will be deemed a screen failure and will be exited from the study.
- Study eyes enrolled with fluid in the primary study eye, may receive treatment during the Week 1 Visit.
- If in the investigator's opinion, the treatment cannot be delayed by approximately 7 days until the Week 1 visit, the subject will be exited from the study as a Screen Failure. NOTE: For the subjects with both eyes with NV-AMD, one eye will be randomly selected as the primary eye during enrollment and the other will be the secondary eye. For subjects with only one eye with NV-AMD, the fellow eye with dry AMD may be enrolled. For such subjects, the NV-AMD eye will be the primary eye and the other eye will be the secondary eye.
- The following data will be collected for the study eye:
- Qualifying diagnosis for the study eye from the subject's medical record
- From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
- Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings
- The subject will receive a general overview (including a description of the device and a review of the NVHO set-up guide) of the self-operation of the NVHO device at the investigational clinic facility by trained study personnel.
- The subject will be (1) reminded that the NVHO device will be delivered to their home and (2) instructed to self-image the study eye(s) once daily using a NVHO device at home for 5 weeks and the Week 1 and Week 5 visits will be scheduled.
- Collect AEs, if applicable.
Home Set-up with Remote Assistance (NVHO Setup Period)
Following confirmation of subject eligibility at the Enrollment Visit and the subject is enrolled in the study:
- The subject will be contacted by the NVDC to verify their delivery address.
- The device will be delivered to the subject's home, with confirmation sent back to the NVDC.
- Remote support is available by the Notal Vision Diagnostic Clinic (NVDC) via phone during normal business hours, if needed.
- The subject will follow the steps detailed in the Set-up Guide included in the box. This is considered NVHO Setup Period. Note: A care giver, family member or friend is allowed to assist. At most four additional calibrations can be performed, on the same day or different consecutive days, for each study eye if the calibration is not successful. Note: If an eye cannot calibrate during 5 separate attempts, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
- Collect AEs, if applicable.
In-Home Phase (Day 1 to Day 35 post NVHO Setup Period) Following set-up of the NVHO,
- Day 1: The subject will perform the first self-imaging session with the NVHO device on both eyes followed by automated transmission of the scans. This first session will be considered a practice session.
- Days 2-35: The subject will perform one self-imaging session each day on the study eye(s) with the NVHO device followed by automated transmission. Each scan has a reliability score provided by the NVHO. Note: If an eye fails to self-image five consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
- Collect AEs, if applicable, as reported by telephone call or office visit to the investigational site.
Week 1 (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit one week after the NVHO Setup Period (Home Set-up). The sponsor will provide transportation upon request. At this visit, the exams will be conducted in the following order:
- Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
- Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
- Initiate standard of care and treatment, if necessary.
- Collect AEs, if applicable. Week 5 / Exit (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit five weeks after the NVHO Setup Period (Home Set-up). At this visit, the exams will be conducted in the following order:
- Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
- Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
- Initiate standard of care and treatment, if necessary.
- Collect AEs, if applicable.
- Exit subject from the study.
What is being measured
The primary outcome is the main question the study is designed to answer.
Positive percent agreement
Positive percent agreement (PPA) of fluid status when comparing the fluid status in the central 3mm X 3mm of the NVHO volume scan graded by an independent reading center to the fluid status in the central 3mm X 3mm of Cirrus volume scan graded by an independent reading center.
Measured: 1 month following reading center grading completion
Negative percent agreement
Negative percent agreement (NPA) of fluid status when comparing the fluid status in the central 3mm X 3mm of the NVHO volume scan graded by an independent reading center to the fluid status in the central 3mm X 3mm Cirrus volume scan graded by an independent reading center.
Measured: 1 month following reading center grading completion
Percentage of subjects who successfully completed the setup of the NVHO device
Percentage of subjects who successfully completed the setup of the NVHO, indicated by the initiation of the tutorial.
Measured: 5-10 minutes
Percentage of subjects who Successful completed NVHO self-imaging
Percentage of subjects who Successful completed NVHO self-imaging, namely a volume macular scan has been captured.
Measured: 2-3 minutes
Secondary outcomes (2)
Percentage of all sessions that were transmission successfully
Percentage of sessions transmitted successfully to the Notal Health Cloud to the Notal Health Cloud .
Measured: 10-15 minutes
Percentage of sessions containing self-imaging that were transmitted successfully
Percentage of sessions containing self-imaging that were transmitted successfully to the Notal Health Cloud.
Measured: 10-15 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2021
- Study start17 Jun 2021
- Primary completion30 Jul 2022 (estimated)
- Study completion30 Aug 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular Age-related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Notal Vision Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gidi Benyamini, MD, Study director, Druyanov 5, Tel Aviv Israel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04907409
- Sponsor's protocol ID
- C2021.001
- Status last verified
- Jan 2022
- First submitted
- 25 May 2021
- Last updated
- 9 Mar 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Home OCT Fluid Visualization Agreement Study at Multiple Retinal Clinics With Placement of One Home OCT Device in the Home of Each NV-AMD Subject in the US for 5 Weeks
- ClinicalTrials.gov ID
- NCT04907409
- Acronym / sponsor ID
- C2021.001
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Notal Vision Inc.Industry (pharma, biotech, devices)
- Study start
- 17 Jun 2021 (actual)
- Primary completion
- 30 Jul 2022 (estimated)
- Study completion
- 30 Aug 2022 (estimated)
- First posted
- 28 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.
Detailed description
The objectives of this study are to (1) evaluate the agreement, via positive percent agreement (PPA) and negative percent agreement (NPA), between OCT images captured by the NVHO and by the Zeiss Cirrus HD-OCT in the visualization of fluid as identified by a RC, in the central 10 degrees of the macula of NV-AMD patients, and (2) evaluate the ability of subjects diagnosed with NV-AMD to set up the device and self-image their eyes at home with the NVHO device (rate of successful imaging attempts).Description of Study Visits and Procedures:
Enrollment Visit:
At this visit, the exams will be conducted in the following order:
- Subject will be informed concerning the study and sign the Informed Consent Form (ICF) prior to the conduct of any study procedures.
- The following data will be collected for each study subject:
- Subject's date of birth (DOB) (if allowed) or age
- Gender
- Race
- Ethnicity
- Level of education
- Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma), will be performed on both eyes on the day of the visit.
- Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mm X 6mm, 512 X 128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
- One or both eye(s) of the subject that meets all screening criteria, including having a diagnosis of NV-AMD in at least one eye previously or at the enrolment visit, will be enrolled in the study.
- Subjects who do not meet all screening criteria will be deemed a screen failure and will be exited from the study.
- Study eyes enrolled with fluid in the primary study eye, may receive treatment during the Week 1 Visit.
- If in the investigator's opinion, the treatment cannot be delayed by approximately 7 days until the Week 1 visit, the subject will be exited from the study as a Screen Failure. NOTE: For the subjects with both eyes with NV-AMD, one eye will be randomly selected as the primary eye during enrollment and the other will be the secondary eye. For subjects with only one eye with NV-AMD, the fellow eye with dry AMD may be enrolled. For such subjects, the NV-AMD eye will be the primary eye and the other eye will be the secondary eye.
- The following data will be collected for the study eye:
- Qualifying diagnosis for the study eye from the subject's medical record
- From the subject's medical record, the presence of other ophthalmic conditions including but not limited to:
- Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings
- The subject will receive a general overview (including a description of the device and a review of the NVHO set-up guide) of the self-operation of the NVHO device at the investigational clinic facility by trained study personnel.
- The subject will be (1) reminded that the NVHO device will be delivered to their home and (2) instructed to self-image the study eye(s) once daily using a NVHO device at home for 5 weeks and the Week 1 and Week 5 visits will be scheduled.
- Collect AEs, if applicable.
Home Set-up with Remote Assistance (NVHO Setup Period)
Following confirmation of subject eligibility at the Enrollment Visit and the subject is enrolled in the study:
- The subject will be contacted by the NVDC to verify their delivery address.
- The device will be delivered to the subject's home, with confirmation sent back to the NVDC.
- Remote support is available by the Notal Vision Diagnostic Clinic (NVDC) via phone during normal business hours, if needed.
- The subject will follow the steps detailed in the Set-up Guide included in the box. This is considered NVHO Setup Period. Note: A care giver, family member or friend is allowed to assist. At most four additional calibrations can be performed, on the same day or different consecutive days, for each study eye if the calibration is not successful. Note: If an eye cannot calibrate during 5 separate attempts, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
- Collect AEs, if applicable.
In-Home Phase (Day 1 to Day 35 post NVHO Setup Period) Following set-up of the NVHO,
- Day 1: The subject will perform the first self-imaging session with the NVHO device on both eyes followed by automated transmission of the scans. This first session will be considered a practice session.
- Days 2-35: The subject will perform one self-imaging session each day on the study eye(s) with the NVHO device followed by automated transmission. Each scan has a reliability score provided by the NVHO. Note: If an eye fails to self-image five consecutive times, the subject will be notified by the NVDC to discontinue self-imaging this eye and NVDC will collect the corresponding information such as the corresponding eye, self-image discontinuation reason, and the self-image stopping date. If there is a fellow eye also enrolled in the study, the fellow eye will continue.
- Collect AEs, if applicable, as reported by telephone call or office visit to the investigational site.
Week 1 (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit one week after the NVHO Setup Period (Home Set-up). The sponsor will provide transportation upon request. At this visit, the exams will be conducted in the following order:
- Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
- Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
- Initiate standard of care and treatment, if necessary.
- Collect AEs, if applicable. Week 5 / Exit (Post NVHO Setup Period)
Subjects will return to the clinic for an office visit five weeks after the NVHO Setup Period (Home Set-up). At this visit, the exams will be conducted in the following order:
- Eye exams, including Snellen BCVA and subjective symptoms (visual distortions, blurry vision, and scotoma) will be performed on both eyes on the day of the visit.
- Both eyes of the subject will be imaged using a commercial Zeiss Cirrus OCT using the 6mmX6mm, 512X128 volume scan program, with a maximum of three attempts for each eye to reach an acceptable image quality per the Cirrus User's Guide and reviewed by the PI to determine fluid status.
- Initiate standard of care and treatment, if necessary.
- Collect AEs, if applicable.
- Exit subject from the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult subjects diagnosed with neovascular age-related macular degeneration (NV-AMD) in at least one eye at the time of enrollment.
Key inclusion criteria (7 listed)
- Subjects must have the ability to speak, read and understand English.
- Ability to understand and agree to contents of informed consent either in writing or verbally.
- Age 55 or older at the Enrollment Visit.
- Adults diagnosed with NV-AMD in at least one eye based on the subject's medical record. Fellow eyes diagnosed with dry AMD may be included as secondary eyes to a primary eye diagnosed with NV-AMD.
- Note: eyes whit other pathologies including pseudocysts, outer retinal tabulations, pigments epithelial, detachments, hemorrhage, sub retinal hyper reflective material (SHRM), geographic atrophy and sub RPE, hypo reflective areas can be enrolled.
Key exclusion criteria (3 listed)
- Anti-VEGF treatment for NV-AMD in the study eye(s) at the screening visit.
- Any other retinal disease requiring steroidal or anti-VEGF injections.
- Prior experience with the NVHO device.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Positive percent agreement
Time frame: 1 month following reading center grading completion
Positive percent agreement (PPA) of fluid status when comparing the fluid status in the central 3mm X 3mm of the NVHO volume scan graded by an independent reading center to the fluid status in the central 3mm X 3mm of Cirrus volume scan graded by an independent reading center.
Negative percent agreement
Time frame: 1 month following reading center grading completion
Negative percent agreement (NPA) of fluid status when comparing the fluid status in the central 3mm X 3mm of the NVHO volume scan graded by an independent reading center to the fluid status in the central 3mm X 3mm Cirrus volume scan graded by an independent reading center.
Percentage of subjects who successfully completed the setup of the NVHO device
Time frame: 5-10 minutes
Percentage of subjects who successfully completed the setup of the NVHO, indicated by the initiation of the tutorial.
Percentage of subjects who Successful completed NVHO self-imaging
Time frame: 2-3 minutes
Percentage of subjects who Successful completed NVHO self-imaging, namely a volume macular scan has been captured.
2 secondary outcomes
Percentage of all sessions that were transmission successfully
Time frame: 10-15 minutes
Percentage of sessions containing self-imaging that were transmitted successfully
Time frame: 10-15 minutes
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2022.
Related trials for Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 3
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Neovascular Age-related Macular Degeneration (nAMD)
Active, not recruitingPhase 2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular Age-related Macular Degeneration
RecruitingPhase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-Related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gidi Benyamini, MD study director
Druyanov 5, Tel Aviv Israel
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neovascular Age-related Macular Degeneration, run by Notal Vision Inc. at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Theresa Landry, PhD (18174807964, theresa.landry@notalvision.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Positive percent agreement (time frame: 1 month following reading center grading completion). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2022.